Plasma concentrations of isoniazid and rifampin are decreased in adult pulmonary tuberculosis patients with diabetes mellitus
Aylin Babalik,Ismail H. Ulus,Nadi Bakirci,Tülin Kuyucu,Hüseyin Arpağ,Lale Dagyildizi,Esen Capaner +6 more
Reads0
Chats0
TLDR
In this paper, the authors showed that plasma concentrations of isoniazid and rifampin were greatly reduced in diabetic tuberculosis patients, but not pyrazinamide and ethambutol concentrations.Abstract:
Plasma isoniazid and rifampin concentrations, but not pyrazinamide and ethambutol concentrations, were decreased by about 50% (P < 0.05) in diabetic pulmonary tuberculosis patients. The prevalences of subnormal plasma isoniazid, rifampin, pyrazinamide, and ethambutol concentrations were 49% or 100% (P < 0.01), 66% or 100% (P < 0.05), 30% or 50% (P = 0.198), and 32% or 21% (P = 0.742) in nondiabetic or diabetic tuberculosis patients, respectively. These data show that plasma concentrations of isoniazid and rifampin were greatly reduced in diabetic tuberculosis patients.read more
Citations
More filters
Journal ArticleDOI
Diabetes and Tuberculosis.
TL;DR: This chapter summarizes the current epidemiological, clinical, and immunological knowledge on TB and DM and their clinical and public health implications, including the underlying mechanisms for TB risk in DM patients and theirclinical and sociodemographic characteristics that distinguish them from TB patients without DM.
Journal ArticleDOI
The influence of diabetes, glycemic control, and diabetes-related comorbidities on pulmonary tuberculosis.
Chen Yuan Chiang,Kuan Jen Bai,Hsien-Ho Lin,Shun Tien Chien,Jen Jyh Lee,Donald A. Enarson,Ting I. Lee,Ming Chih Yu +7 more
TL;DR: Poor glycemic control is associated with poor TB treatment outcome and improved gly glucose control may reduce the influence of diabetes on TB.
Journal ArticleDOI
Impact of diabetes on the natural history of tuberculosis.
TL;DR: The mechanisms by which type 2 diabetes mellitus patients have a higher risk of Mtb infection and TB development, present with signs and symptoms indicative of a more infectious TB infection, and are more likely to have adverse TB treatment outcomes, including death are evaluated.
Journal ArticleDOI
Optimizing treatment outcome of first-line anti-tuberculosis drugs: the role of therapeutic drug monitoring
TL;DR: There is a need to better define the key target PK and pharmacodynamic parameters for therapeutic drug monitoring (TDM) of the first-line anti-TB drugs to be efficacious, Cmax (or area under the curve (AUC)) and Cmax/MIC (or AUC/MIC).
Journal ArticleDOI
Clinical Pharmacokinetics and Pharmacodynamics of Rifampicin in Human Tuberculosis
Ahmed A. Abulfathi,Eric H Decloedt,Elin M. Svensson,Elin M. Svensson,Andreas H. Diacon,Peter R. Donald,Helmuth Reuter +6 more
TL;DR: It is encouraging that daily rifampicin doses up to 35 mg/kg were found to be safe and well-tolerated over a period of 12 weeks and high-dose rifampsicin should thus be considered in future studies when constructing potentially shorter regimens.
References
More filters
Journal ArticleDOI
The early bactericidal activity of drugs in patients with pulmonary tuberculosis.
TL;DR: Counts of colony-forming units of Mycobacterium tuberculosis in sputum were done on selective medium during the first 2 wk of treatment of 124 patients with pulmonary tuberculosis, and thiacetazone and p-aminosalicylic acid appeared to be only bacteriostatic.
Journal ArticleDOI
Therapeutic Drug Monitoring in the Treatment of Tuberculosis
TL;DR: Low isoniazid concentrations were associated with poorer clinical and bacteriological outcomes in US Public Health Services (USPHS) TB Trial 22, suggesting that low concentrations of unbound rifapentine may have been responsible, in part, for the worse-than-anticipated performance of this drug in clinical trials.
Journal ArticleDOI
Diabetes and tuberculosis: the impact of the diabetes epidemic on tuberculosis incidence
Catherine R. Stevenson,Nita G. Forouhi,Gojka Roglic,Brian G. Williams,Jeremy A. Lauer,Chirstopher Dye,Nigel Unwin +6 more
TL;DR: Diabetes makes a substantial contribution to the burden of incident tuberculosis in India, and the association is particularly strong for the infectious form of tuberculosis.
Journal ArticleDOI
The Effect of Type 2 Diabetes Mellitus on the Presentation and Treatment Response of Pulmonary Tuberculosis
Bachti Alisjahbana,Edhyana Sahiratmadja,Erni J Nelwan,Anugrah Maya Purwa,Yana Ahmad,Tom H. M. Ottenhoff,R.H.H. Nelwan,Ida Parwati,Jos W. M. van der Meer,Reinout van Crevel +9 more
TL;DR: DM seems to have a negative effect on the outcome of TB treatment, and the underlying mechanisms for the different response to treatment in diabetic patients with TB must be explored.
Journal ArticleDOI
Exposure to Rifampicin Is Strongly Reduced in Patients with Tuberculosis and Type 2 Diabetes
Hanneke M. J. Nijland,Rovina Ruslami,Janneke E. Stalenhoef,Erni J Nelwan,Bachti Alisjahbana,Ron Nelwan,André J. A. M. van der Ven,H. Danusantoso,Rob E. Aarnoutse,Reinout van Crevel +9 more
TL;DR: Exposure to rifampicin was 53% lower in Indonesian patients with tuberculosis and DM, compared with patients with TB only, and Linear regression analysis revealed that higher body weight, the presence of DM, and plasma glucose concentration were correlated with exposure to r ifampsicin.
Related Papers (5)
Diabetes Mellitus Increases the Risk of Active Tuberculosis: A Systematic Review of 13 Observational Studies
Christie Y. Jeon,Megan Murray +1 more